(Photo Courtesy: www.healthcare.globaldata.com)
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period.
However, the company's latest report states that this expansion, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, represents a slow Compound Annual Growth Rate (CAGR) of 3.1%, inhibited by the highly generic nature of the genital herpes treatment space.
According to Dr Daian Cheng, GlobalData's analyst covering infectious diseases, while generic antivirals have been present in the genital herpes therapeutic marketplace for several years, the overall impact of generic erosion is still expected to be substantial across the 7MM.
Dr Cheng explains: "The low price of generic drugs not only will limit the sales of existing treatment, it also poses an entry barrier for new therapies. GlobalData predicts that the patient share of marketed antiviral drugs will further shift from branded to generic versions by 2023.
"Despite these barriers, the rise in the number of treated patients due to natural population increases in the US and five European countries (5EU) will produce moderate market growth. This will be further aided by the launches of Agenus' HerpV and Genocea's GEN-003 during the forecast period."